Edition:
United Kingdom

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

19.39USD
9:00pm BST
Change (% chg)

$-0.53 (-2.66%)
Prev Close
$19.92
Open
$19.96
Day's High
$20.05
Day's Low
$19.35
Volume
435,254
Avg. Vol
96,265
52-wk High
$30.06
52-wk Low
$16.24

Chart for

About

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and... (more)

Overall

Beta: --
Market Cap(Mil.): $828.20
Shares Outstanding(Mil.): 30.00
Dividend: --
Yield (%): --

Financials

  ACRS.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -2.03 -- --
ROI: -38.27 2.00 14.38
ROE: -38.37 3.49 16.08

BRIEF-Aclaris Therapeutics Q1 Loss Per Share $0.98

* ACLARIS THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS

08 May 2018

BRIEF-Aclaris Therapeutics Announces Availability Of Eskata In The U.S.

* ACLARIS THERAPEUTICS ANNOUNCES AVAILABILITY OF ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W)

07 May 2018

BRIEF-Aclaris Therapeutics Names Bryan Reasons Director And Chairman, Audit Committee

* ACLARIS THERAPEUTICS ANNOUNCES APPOINTMENT OF BRYAN REASONS AS A DIRECTOR AND CHAIRMAN OF THE AUDIT COMMITTEE Source text for Eikon: Further company coverage:

24 Apr 2018

BRIEF-Aclaris Says Primary, Secondary, And Exploratory Endpoints Of Phase 2 Trial of A-101 45% Met

* ACLARIS THERAPEUTICS ANNOUNCES POSITIVE UPDATE ON PHASE 2 RESULTS AFTER A 3-MONTH FOLLOW-UP OF A-101 45% TOPICAL SOLUTION FOR POTENTIAL TREATMENT OF COMMON WARTS

19 Mar 2018

BRIEF-Aclaris Therapeutics Q4 Revenue $1.0 Mln

* ACLARIS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS

12 Mar 2018

BRIEF-Aclaris Therapeutics Issues U.S. Patent Covering JAK Inhibitor For Treating Hair Loss Disorders

* ACLARIS THERAPEUTICS ANNOUNCES ISSUANCE OF U.S. PATENT COVERING A JAK INHIBITOR FOR TREATING HAIR LOSS DISORDERS Source text for Eikon: Further company coverage:

09 Mar 2018

BRIEF-Aclaris Therapeutics Signs Agreement With James Alexander Corp

* ACLARIS THERAPEUTICS SAYS ON JAN 24, CO ENTERED INTO COMMERCIAL SUPPLY MANUFACTURING SERVICES AGREEMENT WITH JAMES ALEXANDER CORP - SEC FILING

30 Jan 2018

BRIEF-Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts

* ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS

08 Jan 2018

Competitors

  Price Chg
RXi Pharmaceuticals Corp (RXII.OQ) $2.15 -0.01

Earnings vs. Estimates